Skip to main content
SpringerLink
Log in

Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Introduction

Pancreatic cancer is often diagnosed at late stages, where disease is either locally advanced unresectable or metastatic. Despite advances, long-term survival is relatively non-existent.

Discussion

This review article discusses clinical factors commonly encountered in practice that should be incorporated into the decision-making process to optimize patient outcomes, including performance status, nutrition and cachexia, pain, psychological distress, medical comorbidities, advanced age, and treatment selection.

Conclusion

Identification and optimization of these clinical factors could make a meaningful impact on the patient’s quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society. Cancer Facts and Figures 2016. Atlanta, Ga: American Cancer Society; 2016.

  2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11)

  3. DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. 1999;10(Suppl 4):140–2.

    Article  PubMed  Google Scholar 

  4. Tas F, Sen F, Keskin S, Kilic L, Ibrahim Y. Prognostic factors in metastatic pancreatic cancer: older patients are associated with reduced overall survival. Mol Clin Oncol. 2013;1(4):788–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

  6. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55.

    Article  CAS  PubMed  Google Scholar 

  7. Karnofsky DA and JH Burchenal. The clinical evaluation of chemotherapeutic agents in cancer in Evaluation of chemotherapeutic agents, page 196. New York, Columbia University Press. 1949. Print.

  8. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  9. Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AEGO prospective multicentre cohort. Br J Cancer. 2015;113(7):989–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20(2):143–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  Google Scholar 

  12. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.

    Article  CAS  PubMed  Google Scholar 

  13. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.

    Article  CAS  PubMed  Google Scholar 

  14. Cunningham D, Chau I, Stcken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513–8.

    Article  CAS  PubMed  Google Scholar 

  15. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag. 2007;34(1):94–104.

    Article  Google Scholar 

  16. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980;69(4):491–7.

    Article  CAS  PubMed  Google Scholar 

  17. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8(3):265–9.

    Article  CAS  PubMed  Google Scholar 

  18. Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB. Appetite and cancer-associated anorexia: a review. J Clin Oncol. 2004;22(8):1510–7.

    Article  CAS  PubMed  Google Scholar 

  19. Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Buchler MW, et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer. 2009;9(255):1–9.

    Google Scholar 

  20. Singh SM, Longmire WP, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg. 1990;212(2):132–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jeurnink SM, Steyerberg EW, van Hooft JE, van Eijck CH, Schwartz MP, Vleggaar FP, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc. 2010;71(3):490–9.

    Article  PubMed  Google Scholar 

  22. Barkin JS, Goldberg RI, Sfakianakis GN, Levi J. Pancreatic carcinoma is associated with delayed gastric emptying. Dig Dis Sci. 1986;31(3):265–7.

    Article  CAS  PubMed  Google Scholar 

  23. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol. 2007;5(8):355–63.

    CAS  PubMed  Google Scholar 

  24. Murr MM, Sarr MG, Camilleri M. The surgeon's role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol. 1995;90(12):2147–51.

    CAS  PubMed  Google Scholar 

  25. Woo SM, Joo J, Kim SY, Park SJ, Han SS, Kim TH, et al. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology. 2016;16(6):1099–105.

    Article  CAS  PubMed  Google Scholar 

  26. Saito T, Hirano K, Isayama H, Nakai Y, Saito K, Umefune G, et al. The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: a prospective cohort study. Pancreas. 2017;46(3):341–6.

    Article  CAS  PubMed  Google Scholar 

  27. Landers A, Muircroft W, Brown H. Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. BMJ Support Palliat Care. 2016;6(1):75–9.

    Article  PubMed  Google Scholar 

  28. Nemer L, Krishna SG, Shah ZK, Conwell DL, Cruz-Monserrate Z, Dillhoff M, et al. Predictors of pancreatic cancer-associated weight loss and nutritional interventions. Pancreas. 2017;46(9):1152–7.

    Article  PubMed  Google Scholar 

  29. Berry AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. Nutr Clin Pract. 2014;29(3):312–21.

    Article  CAS  PubMed  Google Scholar 

  30. Ferrie S, Graham C, Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutr Clin Pract. 2011;26(3):349–51.

    Article  PubMed  Google Scholar 

  31. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathopysiological concentrations. Am J Physiol. 1996;270(6):1394–402.

    Google Scholar 

  32. Arthur ST, Van Doren BA, Roy D, Noone JM, Zacherle E, Blanchette CM. Cachexia among US cancer patients. J Med Econ. 2016;19(9):874–80.

    Article  PubMed  Google Scholar 

  33. Asakawa A, Inui A, Kaga O, Yuzuriha H, Nagata T, Ueno N, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120(2):337–45.

    Article  CAS  PubMed  Google Scholar 

  34. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides. 1999;33(5):415–24.

    Article  CAS  PubMed  Google Scholar 

  35. King PJ, Widdowson PS, Doods H, Williams G. Effect of cytokines on hypothalamic neuropeptide Y release in vitro. Peptides. 2000;21(1):143–6.

    Article  CAS  PubMed  Google Scholar 

  36. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994;219(4):325–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 2007;69(1):113–7.

    Article  PubMed  Google Scholar 

  38. Stall-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol. 1995;13(10):2600–5.

    Article  Google Scholar 

  39. Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ. Purification and characterization of a tumor lipid-moblizing factor. Cancer Res. 1998;58(11):2353–8.

    CAS  PubMed  Google Scholar 

  40. Baracos VE, DeVivo CD, Hoyle DH, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995;268(5):996–1006.

    Google Scholar 

  41. Costelli P, Baccino FM. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care. 2003;6(4):407–12.

    CAS  PubMed  Google Scholar 

  42. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer. 2001;84(12):1599–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014;20(28):9361–73.

    PubMed  PubMed Central  Google Scholar 

  44. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974;33(6):1607–9.

    Article  CAS  PubMed  Google Scholar 

  45. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985;69(7–8):751–4.

    CAS  PubMed  Google Scholar 

  46. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. 82(13). 1990:1127–32.

  47. Gartner S, Kruger J, Aghdassi AA, Steveling A, Simon P, Lerch MM, et al. Nutrition in pancreatic cancer: a review. Gastrointestinal Tumors. 2016;2(4):195–202.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Mochamat CH, Marinova M, Kaasa S, Stieber C, Conrad R, Radbruch L, et al. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia: a European Palliative Care Research Centre cachexia project. J Cachexia Sarcopenia Muscle. 2017;8(1):25–39.

    Article  CAS  PubMed  Google Scholar 

  49. Werner K, Kullenberg de Gaudry D, Taylor LA, Keck T, Unger C, Hopt UT, et al. Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil- a randomized controlled double-blind trial. Lipids Health Dis. 2017;16(1):104.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2(18):1–19.

    Google Scholar 

  51. Loveman C. Incyte announces decision to discontinue JANUS studies of Ruxolitinib plus Capecitabine in patients with advanced or metastatic pancreatic cancer. BusinessWire 2016.

  52. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00815685, A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients with Cancer Cachexia.

  53. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00329615, Insulin Treatment in Cancer Cachexia.

  54. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01395914, Anamorelin HCl in the treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3).

  55. Koulouris AI, Banim P, Hart AR. Pain in patients with pancreatic cancer: prevalence, mechanisms, management and future developments. Dig Dis Sci. 2017;62(4):861–70.

    Article  CAS  PubMed  Google Scholar 

  56. Quigley C. Opioids in people with cancer-related pain. BMJ Clin Evid. 2008;7:2408–24.

    Google Scholar 

  57. Dobosz L, Kaczor M, Stefaniak TJ. Pain in pancreatic cancer: review of medical and surgical remedies. ANZ J Surg. 2016;86(10):756–61.

    Article  PubMed  Google Scholar 

  58. Sharma V, Rana SS, Bhasin DK. Medical management of pain in chronic pancreatitis. Trop Gastroenterol. 2014;35(4):205–11.

    Article  PubMed  Google Scholar 

  59. Plancarte R, Velazquez R, Patt RB. Neurolytic blocks of the sympathetic axis. Cancer Pain. Philadelphia, JB Lippincott Company; 1993. p. 384–420.

  60. Gimenez A, Martinez-Noguera A, Donoso L, Catala E, Serra R. Percutaneous neurolysis of the celiac plexus via the anterior approach with sonographic guidance. Am J Roentgenol. 1993;161(5):1061–3.

    Article  CAS  Google Scholar 

  61. Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized control trial. J Am Med Assoc. 2004;291(9):1092–9.

    Article  CAS  Google Scholar 

  62. Arcidiacono PG, Calori G, Carrara S, McNicol ED, and PA Testoni. Celiac plexus block for pancreatic cancer pain in adults. Cochrane database systemic review. 3:CD007519. 2011.

  63. Amr YM, Makhartia MY. Neurolytic sympathectomy in the management of cancer pain-time effect: a prospective, randomized multicenter study. J Pain Symptom Manag. 2014;48(5):944–56.

    Article  Google Scholar 

  64. TK O, Lee WJ, Woo SM, Kim NW, Yim J, Kim DH. Impact of celiac plexus Neurolysis on survival in patients with unresectable pancreatic cancer: a retrospective, propensity score matching analysis. Pain Physician. 2017;20(3):E357–65.

    Google Scholar 

  65. Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer. 1988;61(6):1110–6.

    Article  CAS  PubMed  Google Scholar 

  66. Lahoud MJ, Kourie HR, Antoun J, El Osta L, Ghosn M. Road map for pain management in pancreatic cancer: a review. World J Gastrointest Oncol. 2016;8(8):599–606.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Ceha HM, van Tienhoven G, Gouma DJ, Veenhof CH, Schneider CJ, Rauws EA, et al. Feasability and efficacy of high dose conformational radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer. 2000;89(11):2222–9.

    Article  CAS  PubMed  Google Scholar 

  68. Morganti AG, Trodella L, Valenti V, Barbi S, Macchia G, Mantini G, et al. Pain relief with short-term irradiation in locally advanced carcinoma of the pancreas. J Palliat Care. 2003;19(4):258–62.

    PubMed  Google Scholar 

  69. Kua J. The prevalence of psychological and psychiatric sequelae of cancer in the elderly—how much do we know? Ann Acad Med. 2005;34(3):250–6.

    CAS  Google Scholar 

  70. Vinokur AD, Threatt BA, Vinokur-Kaplan D, Satariano WA. The process of recovery from breast cancer for younger and older patients. Changes during the first year. Cancer. 1990;65(5):1242–54.

    Article  CAS  PubMed  Google Scholar 

  71. Langa KM, Valenstein MA, Fendrick AM, Kabeto MU, Vijan S. Extent and cost of informal caregiving for older Americans with symptoms of depression. Am J Psychiatr. 2004;161(5):857–63.

    Article  PubMed  Google Scholar 

  72. Fras I, Litin EM, Pearson JS. Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. Am J Psychiatr. 1967;123(12):1553–62.

    Article  CAS  PubMed  Google Scholar 

  73. Joffe RT, Rubinow DR, Denicoff KD, Maher M, Sindelar WF. Depression and carcinoma of the pancreas. Gen Hosp Psychiatry. 1986;8(4):241–5.

    Article  CAS  PubMed  Google Scholar 

  74. Pop VV, Seicean A, Lupan I, Samasca G, CC Burz. IL-6 roles—molecular pathway and clinical implication in pancreatic cancer—a systematic review. Immunol Lett. 2017;181:45–50.

    Article  CAS  PubMed  Google Scholar 

  75. Breitbart W, Rosenfeld B, Tobias K, Pessin H, GY K, Yuan J, et al. Depression, cytokines, and pancreatic cancer. Psychooncology. 2014;23(3):339–45.

    Article  PubMed  Google Scholar 

  76. Botwinick IC, Pursell L, Yu G, Cooper T, Mann JJ, Chabot JA. A biological basis for depression in pancreatic cancer. HPB (Oxford). 2014;16(8):740–3.

    Article  Google Scholar 

  77. Penninx BW, Guralnik JM, Ferrucci L. Depressive symptoms and physical decline in community-dwelling older persons. JAMA. 1998;279(21):1720–6.

    Article  CAS  PubMed  Google Scholar 

  78. Engebretson A, Matrisian L, Thompson C. Pancreatic cancer: patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. Pancreatology. 2015;15(6):701–7.

    Article  PubMed  Google Scholar 

  79. Seeman TE, Berkman LF, Kohout F, Lacroix A, Glynn R, Blazer D. Intercommunity variations in the association between social ties and mortality in the elderly: a comparative analysis of three communities. Ann Epidemiol. 1993;3(4):325–35.

    Article  CAS  PubMed  Google Scholar 

  80. Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2015;6:CD011006.

    Google Scholar 

  81. Akechi T, Okuyama T, Onishi J, Morita T, Furukawa TA. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev. 2008;2:CD005537.

    Google Scholar 

  82. Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D. A structured psychiatric intervention for cancer patients: changes in over time in methods of coping and affective disturbance. Arch Gen Psychiatry. 1990;47(8):720–5.

    Article  CAS  PubMed  Google Scholar 

  83. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2(8668):888–91.

    Article  CAS  PubMed  Google Scholar 

  84. Basch E. The rationale for collecting patient-reported symptoms during routine chemotherapy. Am Soc Clin Oncol educ book. Am Soc Clin Oncol Meet 161–65. 2014

  85. Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliu J. Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016;22(2):764–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996;124(6):577–84.

    Article  CAS  PubMed  Google Scholar 

  87. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120(2):104–10.

    Article  CAS  PubMed  Google Scholar 

  88. Hines RB, Chatla C, Bumpers HL, Waterbor JW, McGwin G, Funkhouser E, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol. 2009;27(26):4339–45.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. Age and comorbiditiy as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group Trials. J Clin Oncol. 2008;26(1):54–9.

    Article  CAS  PubMed  Google Scholar 

  90. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6:546–58.

    Article  CAS  PubMed  Google Scholar 

  91. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30(8):1385–407.

    Article  CAS  PubMed  Google Scholar 

  92. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.

    Article  CAS  PubMed  Google Scholar 

  93. Connor SR, Pyenson B, Fitch K, Spence C, Iwasaki K. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manag. 2007;33(3):238–46.

    Article  Google Scholar 

  94. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 2.2017). https://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf

  95. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet. 2016;387(10018):545–57.

    Article  CAS  PubMed  Google Scholar 

  96. Golan T, Sela T, Margalit O, Amit U, Halpern N, Aderka D, Shmueli ES, Urban D, and YR Lawrence. Short and long-term survival in metastatic pancreatic adenocarcinoma, 1993–2013. J Clin Oncol 35 (suppl 4S, abstract 232). 2017.

  97. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.

    Article  CAS  PubMed  Google Scholar 

  99. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18(9):1202–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, University of Florida College of Medicine, 1600 SW Archer Road, Gainesville, FL, 32610, USA

    William Paul Skelton IV, Hiral Parekh, Jason S. Starr & Thomas J. George Jr

  2. Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA

    Jose Trevino, Jessica Cioffi & Steven Hughes

Authors
  1. William Paul Skelton IV
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiral Parekh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jason S. Starr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jose Trevino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jessica Cioffi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas J. George Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to William Paul Skelton IV or Thomas J. George Jr.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Skelton, W.P., Parekh, H., Starr, J. et al. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Canc 49, 1–8 (2018). https://doi.org/10.1007/s12029-017-0021-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-0021-z

Keywords

Search

Navigation